Description
Oxymetholone (Anadrol, Anapolon) is a synthetic dihydrotestosterone derivative with 17α-methyl group and 2-hydroxymethylene modification at the A-ring. The substance was developed in the 1960s and is clinically approved for treatment of anemia, HIV wasting, and Fanconi aplasia.
Per study reports Oxymetholone acts via the androgen receptor but has additional progestagenic activity - although the substance doesn’t aromatize directly (DHT derivative). The strong water retention and typical estrogen-mediated effects presumably stem from direct estrogen receptor activation by the molecule itself, without aromatase conversion.
Pharmacokinetically orally bioavailable with about 8-9 hour half-life. Known for very rapid action onset times: marked changes in water retention, pump, and research findings on muscle mass within 1-2 weeks.
Known effects in studies: strong hepatotoxicity (higher than under Anavar, comparable to Dianabol), pronounced water retention, hypertension, unfavorable lipid profile, paradoxical estrogen effects without aromatization, HPG suppression. With long use, liver adenomas documented.
In recreational research practice Anadrol is often used as kickstart compound in the first 4-6 weeks of long cycles because action sets in quickly and the long test ester hasn’t yet plateaued. Longer Anadrol cycles are problematic due to hepatotoxicity.
Oxymetholone is on the WADA banned list.
You can order Oxymetholone as oral tablets in one bottle with 50mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Oxymetholone is among the most potent and at the same time harshest oral anabolics, sitting clearly in the upper range of the risk scale. The effects documented in the literature are pronounced and primarily affect the liver, blood pressure and hormonal balance.
Documented in studies and the user literature:
- Strong liver strain: as a 17α-methyl steroid, Oxymetholone is markedly hepatotoxic, comparable to Dianabol. Consistent ALT/AST elevations and, with long use, liver adenomas are documented.
- Water retention and blood pressure: studies describe pronounced water retention and hypertension, and paradoxical estrogenic effects occur without aromatization.
- Lipid profile: an unfavorable lipid profile with cardiovascular relevance is documented.
- Suppression of natural production: the literature describes a marked suppression of the HPG axis, and the progestagenic activity can additionally raise prolactin.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection - British Journal of Nutrition 1996, Hengge et al: Clinical study on weight and lean mass gain in HIV-associated wasting.
- Review of oxymetholone: a 17α-alkylated anabolic-androgenic steroid - Clinical Therapeutics 2001, Pavlatos et al: Pharmacological review of action, pharmacokinetics and safety profile.
- Effect of Oxymetholone in Refractory Anemia - Archives of Internal Medicine 1964, Sanchez-Medal et al: Classic clinical study on hematological response in refractory anemia.
- Efficacy of Oxymetholone in Severe and Nonsevere Acquired Aplastic Anemia: A Propensity Score Matching Analysis - Journal of Blood Medicine 2022, Pengthina et al: Modern outcome analysis on efficacy in aplastic anemia.
- Oxymetholone hepatotoxicity enhanced by concomitant use of cyclosporin A in a bone marrow transplant patient - Clinical and Laboratory Haematology 1994, Wood et al: Case report on liver toxicity under co-medication.
